The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 06, 2020

Filed:

Mar. 28, 2017
Applicants:

Precedo Pharmaceuticals Co., Ltd, Hefei, Anhui, CN;

Hefei Gracevo Bio-medicine Co., Ltd, Hefei, Anhui, CN;

Inventors:

Qingsong Liu, Anhui, CN;

Jing Liu, Anhui, CN;

Qiang Wang, Anhui, CN;

Beilei Wang, Anhui, CN;

Feiyang Liu, Anhui, CN;

Shuang Qi, Anhui, CN;

Ziping Qi, Anhui, CN;

Fengming Zou, Anhui, CN;

Cheng Chen, Anhui, CN;

Wenchao Wang, Anhui, CN;

Chen Hu, Anhui, CN;

Xiaochuan Liu, Anhui, CN;

Wei Wang, Anhui, CN;

Aoli Wang, Anhui, CN;

Li Wang, Anhui, CN;

Zhenquan Hu, Anhui, CN;

Tao Ren, Anhui, CN;

Assignees:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 401/06 (2006.01); C07D 401/14 (2006.01); A61K 31/454 (2006.01); A61K 31/4545 (2006.01); C07D 409/14 (2006.01); C07D 211/44 (2006.01); C07D 413/14 (2006.01); A61K 31/45 (2006.01); C07D 413/04 (2006.01); C07D 401/04 (2006.01); A61P 35/00 (2006.01); A61K 31/445 (2006.01); C07D 413/06 (2006.01);
U.S. Cl.
CPC ...
C07D 401/06 (2013.01); A61K 31/445 (2013.01); A61K 31/45 (2013.01); A61K 31/454 (2013.01); A61K 31/4545 (2013.01); A61P 35/00 (2018.01); C07D 211/44 (2013.01); C07D 401/04 (2013.01); C07D 401/14 (2013.01); C07D 409/14 (2013.01); C07D 413/04 (2013.01); C07D 413/06 (2013.01); C07D 413/14 (2013.01);
Abstract

The present invention provides a compound represented by formula (I), or a pharmaceutically acceptable salt, a solvate, an ester, an acid, a metabolite or a prodrug thereof. The compound itself in the present invention or in combination with at least one therapeutic agent can be used for preventing or treating diseases, disorders or symptoms caused by the adjustment of the activity of tyrosine kinase C-KIT, or affected by the activity of the tyrosine kinase C-KIT or involving in the activity of the tyrosine kinase C-KIT, especially cancers or other cell proliferation diseases.


Find Patent Forward Citations

Loading…